Beranda › Kanker Payudara › New York › Rochester
Uji klinis Kanker Payudara di Rochester, NY
15 studi untuk Kanker Payudara mencari peserta di lokasi sekitar Rochester (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Menerima pesertaFase 2
- University of Rochester Medical Center, Rochester
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Menerima peserta
- University of Rochester (URMC), Rochester
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Menerima pesertaFase 2
- Wilmot Cancer Institute, Rochester
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Menerima pesertaFase 3
- Rochester General Hospital Lipson Cancer Institute, Rochester
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Menerima pesertaFase 3
- University of Rochester Medical, Rochester
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Menerima pesertaFase 1
- Wilmot Cancer Institute, Rochester
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Menerima pesertaFase 2
- University of Rochester Medical Center, Rochester
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Menerima pesertaFase 3
- Pluta Cancer Center, Rochester
- University of Rochester, Rochester
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Menerima pesertaFase 1
- University of Rochester - Wilmot Cancer Institute, Rochester
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Menerima pesertaFase 2
- University of Rochester Wilmot Cancer Institute, Rochester
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Menerima pesertaFase 3
- Wilmot Cancer Institute Radiation Oncology at Greece, Rochester
- Highland Hospital, Rochester
- Pluta Cancer Center, Rochester
- dan 3 lainnya
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
Menerima peserta
- University of Rochester, Rochester
Access to Genetic Testing in Underserved Patients With Cancer
Menerima pesertaSukarelawan sehat diterima
- University of Rochester, Rochester
Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
Menerima pesertaFase 2
- University of Rochester, Rochester
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Menerima pesertaStudi observasional
- University of Rochester - Pluta Cancer Center, Rochester
Uji klinis Kanker Payudara di kota lain
- New York City, NY136 studi
- Houston, TX126 studi
- Boston, MA112 studi
- Nashville, TN81 studi
- Los Angeles, CA73 studi
- Edison, NJ68 studi
- St. Louis, MO64 studi
- Queens, NY64 studi
- Durham, NC64 studi
- Chicago, IL59 studi
- Philadelphia, PA56 studi
- Dallas, TX55 studi
Studi lain di Rochester
- Leukemia Mieloid Akut16 studi
- Kanker Paru15 studi
- Kanker (semua jenis)14 studi
- Obesitas14 studi
- Kelebihan Berat Badan13 studi
- Kanker Paru Non-Sel Kecil13 studi
- Kanker Prostat10 studi
- Kanker Metastatik8 studi
- Mieloma Multipel8 studi
- Kanker Kandung Kemih7 studi
- Distrofi Miotonik7 studi
- Kanker Pankreas7 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.